To examine the impact of the anti-human TREM2 agonistic mAb VHB937 in vitro and in vivo in models for neurodegenerative diseases.
No takes yet. Share an insight, caveat, or question.
Stangel et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: